Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial

Samir S. Taneja

doi:10.1016/j.juro.2014.12.078

Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	848-849
Number of pages	2
Journal	Journal of Urology
Volume	193
Issue number	3
DOIs	https://doi.org/10.1016/j.juro.2014.12.078
State	Published - Mar 1 2015

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2014.12.078

Cite this

Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. / Taneja, Samir S.
In: Journal of Urology, Vol. 193, No. 3, 01.03.2015, p. 848-849.

Research output: Contribution to journal › Comment/debate › peer-review

@article{7cbb3575f19d4d06aac1a56f14dd204b,

title = "Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial",

author = "Taneja, {Samir S.}",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/j.juro.2014.12.078",

language = "English (US)",

volume = "193",

pages = "848--849",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Re

T2 - Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial

AU - Taneja, Samir S.

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84922570499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922570499&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.12.078

DO - 10.1016/j.juro.2014.12.078

M3 - Comment/debate

C2 - 25765387

AN - SCOPUS:84922570499

SN - 0022-5347

VL - 193

SP - 848

EP - 849

JO - Journal of Urology

JF - Journal of Urology

IS - 3

ER -

Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this